Francesco Silvestris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5055242/publications.pdf

Version: 2024-02-01

175	6,273	76326	88630
papers	citations	40 h-index	70 g-index

178	178	178	10114
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
2	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. Neuroendocrinology, 2021, 111, 207-216.	2.5	13
3	Susceptibility to ischaemic heart disease: Focusing on genetic variants for ATP-sensitive potassium channel beyond traditional risk factors. European Journal of Preventive Cardiology, 2021, 28, 1495-1500.	1.8	22
4	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. Cardiovascular Drugs and Therapy, 2021, 35, 505-519.	2.6	14
5	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leukemia and Lymphoma, 2021, 62, 337-347.	1.3	2
6	Application of â€œomicsâ€•sciences to the prediction of bone metastases from breast cancer: State of the art. Journal of Bone Oncology, 2021, 26, 100337.	2.4	6
7	First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Scientific Reports, 2021, 11, 4329.	3.3	8
8	Uterine carcinosarcoma: An overview. Critical Reviews in Oncology/Hematology, 2021, 163, 103369.	4.4	16
9	A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. Frontiers in Physiology, 2021, 12, 748895.	2.8	21
10	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. International Journal of Molecular Sciences, 2020, 21, 52.	4.1	38
11	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	2.8	10
12	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 581130.	2.8	7
13	DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers. International Journal of Molecular Sciences, 2020, 21, 6096.	4.1	2
14	Large Extracellular Vesiclesâ€”A New Frontier of Liquid Biopsy in Oncology. International Journal of Molecular Sciences, 2020, 21, 6543.	4.1	17
15	Pulmonary enteric adenocarcinoma: an overview. Expert Reviews in Molecular Medicine, 2020, 22, e1.	3.9	11
16	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	3.2	10
17	Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. Eating and Weight Disorders, 2019, 24, 67-72.	2.5	28
18	Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. Journal of Translational Medicine, 2019, 17, 230.	4.4	41

#	Article	IF	Citations
19	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	3.0	7
20	Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. Frontiers in Oncology, 2019, 9, 521.	2.8	35
21	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987554.	3.2	21
22	Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma. International Journal of Biological Markers, 2019, 34, 421-426.	1.8	8
23	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 2019, 109, 83-99.	2.5	87
24	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. Tumor Biology, 2019, 41, 101042831983713.	1.8	29
25	Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Frontiers in Oncology, 2019, 9, 139.	2.8	10
26	25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 838-844.	1.2	34
27	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. Scientific Reports, 2019, 9, 17276.	3.3	16
28	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology, 2019, 9, 1148.	2.8	90
29	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	3.3	26
30	Gene Fusion in NSCLC. , 2019, , 443-464.		1
31	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
32	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	2.4	153
33	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. British Journal of Cancer, 2019, 120, 294-300.	6.4	25
34	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	3.1	10
35	In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. Human Reproduction, 2018, 33, 464-473.	0.9	90
36	The management of refractory carcinoid syndrome: challenges and opportunities ahead. Journal of Medical Economics, 2018, 21, 241-243.	2.1	1

#	Article	IF	Citations
37	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. OncoImmunology, 2018, 7, e1387706.	4.6	76
38	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget, 2018, 9, 25355-25382.	1.8	34
39	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget, 2018, 9, 20826-20837.	1.8	97
40	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879463.	3.2	317
41	Animal-type melanoma: dog or wolf? A review of the literature and a case report. Expert Reviews in Molecular Medicine, 2018, 20, e5.	3.9	2
42	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	7.7	31
43	Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family. International Journal of Molecular Sciences, 2018, 19, 285.	4.1	14
44	Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 251-259.	1.2	18
45	Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 646-652.	1.2	22
46	Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. Experimental Hematology, 2017, 47, 48-53.	0.4	3
47	ALK gene alterations in cancer: biological aspects and therapeutic implications. Pharmacogenomics, 2017, 18, 277-292.	1.3	8
48	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia and Lymphoma, 2017, 58, 2633-2641.	1.3	19
49	Immuneâ€'related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). Oncology Letters, 2017, 14, 5671-5680.	1.8	54
50	1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells. Experimental Cell Research, 2017, 358, 260-268.	2.6	11
51	Ovarian cancer: Novel molecular aspects for clinical assessment. Critical Reviews in Oncology/Hematology, 2017, 117, 12-29.	4.4	25
52	Characterization of a Rare Nonpathogenic Methylenetetrahydrofolatereductase (MTHFR) Gene Mutation p.Lys215del in a Southern Italian family. Human Mutation, 2017, 38, 120-121.	2.5	2
53	Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene (DPYD). International Journal of Biological Markers, 2017, 32, 357-360.	1.8	3
54	Immune Profile of Obese People and In Vitro Effects of Red Grape Polyphenols on Peripheral Blood Mononuclear Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	20

#	Article	IF	Citations
55	pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. Stem Cell Research and Therapy, 2017, 8, 206.	5.5	25
56	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	1.8	174
57	Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro. Oncotarget, 2017, 8, 22534-22549.	1.8	21
58	Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 16, 270-275.	1.2	12
59	Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 17, 207-212.	1.2	7
60	Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Research, 2017, 37, 3357-3366.	1.1	62
61	Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA). Cancer Genomics and Proteomics, 2017, 14, 173-179.	2.0	29
62	Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	4.0	62
63	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e196-e199.	3.5	15
64	Mediterranean Diet and cancer risk: an open issue. International Journal of Food Sciences and Nutrition, 2016, 67, 593-605.	2.8	29
65	Cilengitide restrains the osteoclastâ€like bone resorbing activity of myeloma plasma cells. British Journal of Haematology, 2016, 173, 59-69.	2.5	10
66	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology, 2016, 103, 321-334.	2.5	19
67	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer, 2016, 16, 87.	2.6	20
68	Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. Oncologist, 2016, 21, 404-417.	3.7	83
69	miRNAs in melanoma: a defined role in tumor progression and metastasis. Expert Review of Clinical Immunology, 2016, 12, 79-89.	3.0	40
70	NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget, 2016, 7, 57414-57429.	1.8	23
71	Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects. BMC Cardiovascular Disorders, 2015, 15, 108.	1.7	52
72	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer, 2015, 15, 692.	2.6	16

#	Article	IF	Citations
73	Erdheimâ€“Chester disease: A systematic review. Critical Reviews in Oncology/Hematology, 2015, 95, 1-11.	4.4	153
74	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	4.4	2
75	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. Journal of Clinical Oncology, 2015, 33, e66-e70.	1.6	5
76	A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression. Stem Cells and Development, 2015, 24, 1457-1470.	2.1	21
77	Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. Journal of Translational Medicine, 2015, 13, .	4.4	0
78	AvÎ²3 integrin: Pathogenetic role in osteotropic tumors. Critical Reviews in Oncology/Hematology, 2015, 96, 183-193.	4.4	38
79	Targeted Therapies for Bone Metastases. Current Clinical Pathology, 2015, , 249-266.	0.0	0
80	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
81	New Insights Into the Molecular Pathogenesis of Langerhans Cell Histiocytosis. Oncologist, 2014, 19, 151-163.	3.7	47
82	The immune escape in melanoma: role of the impaired dendritic cell function. Expert Review of Clinical Immunology, 2014, 10, 1395-1404.	3.0	56
83	Does cilengitide deserve another chance?. Lancet Oncology, The, 2014, 15, e584-e585.	10.7	40
84	PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression. Journal of Bone and Mineral Research, 2014, 29, 55-66.	2.8	53
85	Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer and Metastasis Reviews, 2014, 33, 333-342.	5.9	38
86	Targeting bone metastatic cancer: Role of the mTOR pathway. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 248-254.	7.4	25
87	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Experimental Hematology, 2014, 42, 897-908.e1.	0.4	13
88	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opinion on Biological Therapy, 2014, 14, 15-26.	3.1	17
89	Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2014, 13, 301-305.	1.2	4
90	Immature dendritic cells in multiple myeloma are prone to osteoclastâ€like differentiation through interleukinâ€17<scp>A</scp> stimulation. British Journal of Haematology, 2013, 161, 821-831.	2.5	42

#	Article	IF	Citations
91	Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cellular Signalling, 2013, 25, 1108-1117.	3.6	21
92	Cytotherapies in multiple myeloma: a complementary approach to current treatments?. Expert Opinion on Biological Therapy, 2013, 13, S23-S34.	3.1	4
93	Novel lenalidomide-based combinations for treatment of multiple myeloma. Critical Reviews in Oncology/Hematology, 2013, 85, 9-20.	4.4	11
94	Possible Role of Hyperinsulinemia and Insulin Resistance in Lower Vitamin D Levels in Overweight and Obese Patients. BioMed Research International, 2013, 2013, 1-6.	1.9	28
95	Obesity and Heart Failure. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 51-57.	1.2	36
96	Obesity as a Major Risk Factor for Cancer. Journal of Obesity, 2013, 2013, 1-11.	2.7	669
97	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. Blood, 2013, 122, 4383-4383.	1.4	1
98	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. Critical Reviews in Oncogenesis, 2013, 18, 75-95.	0.4	2
99	Therapeutic approaches to myeloma bone disease: An evolving story. Cancer Treatment Reviews, 2012, 38, 787-797.	7.7	25
100	Abdominal Obesity Is Characterized by Higher Pulse Pressure: Possible Role of Free Triiodothyronine. Journal of Obesity, 2012, 2012, 1-5.	2.7	10
101	Lenalidomide in multiple myeloma: current experimental and clinical data. European Journal of Haematology, 2012, 88, 279-291.	2.2	14
102	In vitro antiâ€myeloma activity of <scp>TRAIL</scp>â€expressing adiposeâ€derived mesenchymal stem cells. British Journal of Haematology, 2012, 157, 586-598.	2.5	46
103	Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL). Blood, 2012, 120, 1645-1645.	1.4	1
104	Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?. Oncologist, 2011, 16, 1040-1048.	3.7	38
105	Arterial hypertension in obesity: relationships with hormone and anthropometric parameters. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 240-247.	2.8	14
106	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation inÂvitro. Experimental Hematology, 2011, 39, 773-783.e1.	0.4	33
107	Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. Stem Cells and Development, 2011, 20, 1-10.	2.1	47
108	Relationship between C3 Levels and Common Carotid Intima-Media Thickness in Overweight and Obese Patients. Obesity Facts, 2011, 4, 159-163.	3.4	11

#	Article	IF	Citations
109	Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy. Current Pharmaceutical Design, 2011, 17, 1979-1983.	1.9	6
110	Cell Fusion and Hyperactive Osteoclastogenesis in Multiple Myeloma. Advances in Experimental Medicine and Biology, 2011, 714, 113-128.	1.6	15
111	Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. Leukemia Research, 2010, 34, 243-249.	0.8	27
112	Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	51
113	Targeted Therapies in Cancer. BioDrugs, 2010, 24, 77-88.	4.6	36
114	Umbilical Cord Mesenchymal Stem Cells: Role of Regulatory Genes in Their Differentiation to Osteoblasts. Stem Cells and Development, 2009, 18, 1211-1220.	2.1	41
115	Boneâ€Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. Oncologist, 2009, 14, 264-275.	3.7	26
116	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. Annals of the New York Academy of Sciences, 2009, 1173, 449-457.	3.8	29
117	Î²3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells. Cancer Research, 2009, 69, 6738-6746.	0.9	32
118	Functional expression of the calcitonin receptor by human T and B cells. Human Immunology, 2009, 70, 678-685.	2.4	9
119	Role of Active Drug Transporters in Refractory Multiple Myeloma. Current Topics in Medicinal Chemistry, 2009, 9, 218-224.	2.1	18
120	Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukinâ€18. Arthritis and Rheumatism, 2008, 58, 251-262.	6.7	207
121	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leukemia Research, 2008, 32, 611-623.	0.8	23
122	Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clinical and Experimental Immunology, 2008, 154, 247-254.	2.6	97
123	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. Clinical Cancer Research, 2008, 14, 6081-6091.	7.0	32
124	Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. Leukemia Research, 2007, 31, 129-138.	0.8	44
125	Increased IL-18 Production by Dendritic Cells in Active Inflammatory Myopathies. Annals of the New York Academy of Sciences, 2007, 1107, 184-192.	3.8	26
126	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1921-1931.	1.3	11

#	Article	IF	Citations
127	Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. Journal of Hypertension, 2006, 24, 1307-1318.	0.5	41
128	Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clinical and Experimental Immunology, 2006, 146, 21-31.	2.6	59
129	Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules. Journal of Virology, 2006, 80, 3923-3934.	3.4	69
130	The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. Annals of the New York Academy of Sciences, 2005, 1051, 421-432.	3.8	43
131	Functional osteoclast-like transformation of cultured human myeloma cell lines. British Journal of Haematology, 2005, 130, 926-938.	2.5	39
132	Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. Autoimmunity Reviews, 2005, 4, 542-548.	5.8	66
133	Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005, 26, 883-891.	2.8	230
134	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology, 2004, 126, 475-486.	2.5	90
135	Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L. Leukemia and Lymphoma, 2004, 45, 377-380.	1.3	16
136	Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma. International Journal of Hematology, 2003, 78, 121-125.	1.6	21
137	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. British Journal of Haematology, 2003, 122, 39-52.	2.5	65
138	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus, 2003, 12, 8-14.	1.6	31
139	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. Leukemia and Lymphoma, 2002, 43, 1527-1533.	1.3	10
140	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood, 2002, 99, 1305-1313.	1.4	97
141	Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma. Reviews in Clinical and Experimental Hematology, 2002, Suppl 1, 39-46.	0.1	1
142	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNÎ²-1a. Journal of the Neurological Sciences, 2001, 186, 65-73.	0.6	5
143	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood, 2001, 97, 1155-1164.	1.4	51
144	Anti-Fas (CD95/Apo-I) Autoantibodies and Soluble Fas Levels Concur in T Cell Depletion in HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2001, 17, 603-614.	1.1	4

#	Article	IF	Citations
145	Immunogenicity of an Eight Amino Acid Domain Shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and Antigenic Analysis. Molecular Medicine, 2000, 6, 494-508.	4.4	4
146	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. Molecular Medicine, 2000, 6, 509-526.	4.4	8
147	Nef protein induces differential effects in CD8+cells from HIV-1-infected patients. European Journal of Clinical Investigation, 1999, 29, 980-991.	3.4	5
148	Urinary loss of immunoglobulin G anti-F(abâ€²)2 and anti-DNA antibody in systemic lupus erythematosus nephritis. Translational Research, 1998, 132, 210-222.	2.3	4
149	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 1998, 28, 127-134.	1.0	48
150	Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. International Journal of Clinical and Laboratory Research, 1998, 28, 215-225.	1.0	11
151	CD8+ /CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. British Journal of Haematology, 1998, 100, 469-477.	2.5	49
152	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology, 1998, 114, 179-188.	2.6	25
153	Cross-reactivity of human igg anti-F(abâ€²)2 antibody with DNA and other nuclear antigens. Arthritis and Rheumatism, 1997, 40, 109-123.	6.7	12
154	Affinity columns containing anti-DNA Id+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin. Arthritis and Rheumatism, 1997, 40, 683-693.	6.7	11
155	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Aids, 1996, 10, 131-141.	2.2	94
156	Shared V-Region Antigens and Cross-Reacting Specificities of Human IgG Anti-F(abâ€²)2and Anti-DNA Antibodies. Clinical Immunology and Immunopathology, 1996, 80, 194-203.	2.0	8
157	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€“infected Patients. Journal of Experimental Medicine, 1996, 184, 2287-2300.	8.5	26
158	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and Î±-interferon therapy. International Journal of Clinical and Laboratory Research, 1995, 25, 79-83.	1.0	9
159	Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Annals of Hematology, 1995, 70, 313-318.	1.8	51
160	Molecular localization of human IgG anti-F(abâ€²)2 reactivity with variable- and constant-region Î» light-chain epitopes. Journal of Clinical Immunology, 1995, 15, 349-362.	3.8	3
161	Autoreactivity in HIV-1 Infection: The Role of Molecular Mimicry. Clinical Immunology and Immunopathology, 1995, 75, 197-205.	2.0	81
162	IgG Anti-F(abâ€²)2 Antibodies from SLE Patients React with Immunodominant Residues in Îº CDRs, but Show Reduced Cκ Region Reactivity. Clinical Immunology and Immunopathology, 1995, 77, 366-373.	2.0	0

#	Article	IF	Citations
163	Expression of F4, 8.12, 3I, and 16/6 Anti-DNA Idiotype-Related Antigens on Cationic Human IgG Myeloma Proteins. Clinical Immunology and Immunopathology, 1994, 73, 215-223.	2.0	3
164	Distribution and Antigenic Analysis of Circulating F(abâ€²)2-Reactive IgG in Patients with HIV-1 Infection. Clinical Immunology and Immunopathology, 1994, 73, 229-234.	2.0	4
165	Molecular Specificities of CD4+ T Cell-Reactive IgM in Human Immunodeficiency Virus (HIV-1) Infection. Clinical Immunology and Immunopathology, 1994, 70, 40-46.	2.0	7
166	Human anti-F(abâ€²)2 antibodies show preferential reactivity for F(abâ€²)2 molecules bearing Î» light chains. Clinical Immunology and Immunopathology, 1992, 65, 176-182.	2.0	2
167	Differential isotype expression and binding properties of T cell-reactive antibodies in human immunodeficiency virus (HIV) infection. Journal of Clinical Immunology, 1992, 12, 107-115.	3.8	2
168	Parallelism of serum anti-F(abâ€²)2 and anti-cationic IgG reactivities in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1991, 59, 256-270.	2.0	4
169	Monoclonal antibodies against human anti-F(abâ€²)2 antibodies react with light chain epitopes. Clinical Immunology and Immunopathology, 1991, 59, 139-155.	2.0	4
170	Distribution of anti-F(abâ€²)2 antibodies and the 16/6 idiotype in systemic lupus erythematosus (SLE) probands and kindreds. Journal of Clinical Immunology, 1989, 9, 462-468.	3.8	5
171	Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. Clinical Immunology and Immunopathology, 1989, 53, 329-340.	2.0	10
172	In vitro inhibition of anti-DNA producing cells from systemic lupus erythematosus patients by autologous anti-F(abâ€²)2 antibodies. Clinical Immunology and Immunopathology, 1987, 42, 50-62.	2.0	17
173	Discrepancy in the expression of autoantibodies in healthy aged individuals. Clinical Immunology and Immunopathology, 1985, 35, 234-244.	2.0	35
174	Studies of anti-f(ab')2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis and Rheumatism, 1984, 27, 1387-1396.	6.7	80
175	New clinical and immunological trends in cryoglobulinemia. Research in Clinic and Laboratory, 1980, 10, 51-57.	0.3	11